The Cost-utility of Early use of High-flow Nasal Cannula in Bronchiolitis

Jefferson Antonio Buendia (jefferson.buendia@gmail.com)
Universidad de Antioquia Facultad de Medicina  https://orcid.org/0000-0003-2404-6612

Ranniery Acuña-Cordero
Hospital Militar Central Cirujano Mayor Dr Cosme Argerich

Carlos E. Rodriguez-Martinez
Universidad Nacional de Colombia

Research

Keywords: health economics, public health, healthcare, asthma, oxygen, cannula

DOI: https://doi.org/10.21203/rs.3.rs-89749/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** High-flow nasal cannula (HFNC) oxygen is a non-invasive ventilation system that was introduced as an alternative to CPAP (continuous positive airway pressure), with a marked increase in its use in pediatric care settings. This study aimed to evaluate the cost-effectiveness of early use of HFNC compared to oxygen by nasal cannula in an infant with bronchiolitis in the emergency setting.

**Methods:** A decision tree model was used to estimate the cost-effectiveness of HFNC compared with oxygen by nasal cannula (control strategy) in an infant with bronchiolitis in the emergency setting. Cost data were obtained from a retrospective study on bronchiolitis from tertiary centers in Rionegro, Colombia, while utilities were collected from the literature.

**Results:** The QALYs per patient calculated in the base-case model were 0.9141 (95% CI 0.913- 0.915) in the HFNC and 0.9105 (95% CI 0.910- 0.911) in control group. The cost per patient was US$368 (95% CI US$ 323- 411) in HFNC and US$441 (95% CI US$ 384-498) per patient in the control group.

**Conclusions:** HFNC in emergency settings was cost-effective for the hospital treatment of an infant with bronchiolitis.

Introduction

High-flow nasal cannula (HFNC) oxygen is a non-invasive ventilation system that was introduced as an alternative to CPAP (continuous positive airway pressure), with a marked increase in its use in pediatric care settings (1−3). In children with bronchiolitis, HFNC has been used as an alternative to CPAP and mechanical ventilation, with adequate tolerance (4−7).

HFNC has been associated with: increases in patients’ functional residual capacity, reductions in the effects of oxygen dilution in trachea compared to NC (nasal cannula), dead space washout, and more compliance in relation to CPAP (8). This physiological effect has been reflected in randomized clinical trials, with significantly lower rates of treatment failure compared to NC, with few severe adverse events or safety issues (9). Despite this evidence and the frequent use of HFNC in the PICU (pediatric intensive care unit) setting, the economic impact of its use in the emergency setting has not yet been evaluated. It is precisely its use in the emergency setting where this system could have the greatest economic impact as a prior alternative to using CPAP or mechanical ventilation (10). This would be significant, especially for hospitals in middle-income countries with scarce health resources, and where this technology could be a cost-saving alternative (11, 12). This study aims to evaluate the cost-effectiveness of HFNC compared to oxygen by nasal cannula in infants with bronchiolitis in the emergency setting.

Methods

**Design**
Cost-utility study that compared HFNC against oxygen by nasal cannula (control group) in infants with bronchiolitis in the emergency setting. The effectiveness outcome was the quality-adjusted life years (QALYs). The analysis was carried out from a societal perspective (including direct and indirect costs). The analytic horizon was an acute episode of bronchiolitis. Given the short time horizon, no type of discount to costs or results was applied. The study protocol was reviewed and approved by the Institutional Review Board of Clinica Somer (No 281015) and the University of Antioquia (No 18/2015).

**Economic model**

A decision tree model was used to estimate the cost-effectiveness of HFNC on bronchiolitis (Figure 1). In the economic model, we defined the following outcomes according to the natural history of bronchiolitis: death, hospitalization with or without acute complications, PICU admission with or without acute complications. Acute complications included: pneumonia, atelectasis, sepsis, pleural effusions, and pneumothoraxes (13, 14).

**Probabilities**

To estimate the probabilities of the model (see Table 1), we performed a systematic review of systematic reviews or RCTs published or observational studies up to January 2020. To identify potentially relevant studies, we carried out searches of computerized databases (MEDLINE, CENTRAL, LILACS, and CINAHL) using the following search strategy: (High flow nasal cannula OR Nasal Cannula OR Nasal Cannulae OR oxygen) AND (Bronchiolitis OR Bronchiolitis, Viral), limited with the terms children OR child OR pediatric OR adolescents OR infants OR preschoolers). No language restrictions were applied. To be included in the model, the studies had to be parallel-group or cross-over RCTs, systematic reviews or RCTs published or observational studies including children between 2 and 18 years of age. Other observational clinical studies obtained during the review of references cited in the published literature were also included (15-22). The computerized search yielded 927 citations and a total of 55 studies were examined in full for possible inclusion. For data to be included in the model, participants in the studies needed to be under the age of 18 years with bronchiolitis and studies needed to evaluate the use of high flow nasal cannula and report at least one of the following outcomes: percentage of hospitalizations or admissions in pediatric intensive care units or acute complications during the period of observation.
### Table 1
Model inputs: morbidity probabilities used in base case and sensitivity analyses

| Model input                                      | Base case value | SA range for one-way sensitivity analyses | Source |
|--------------------------------------------------|-----------------|------------------------------------------|--------|
| **Probability**                                  |                 |                                          |        |
| Hospitalization                                  | 0,25            | 0,01-0,41                                | (21)   |
| PICU, given hospitalization                      | 0,07            | 0,06-0,18                                | (20)   |
| Mortality, given PICU admission                  | 0,009           | 0,001-0,06                               | (16)   |
| Acute complications, given hospitalization       | 0,13            | 0,10-0,20                                | (15)   |
| Acute complications, given PICU admission        | 0,15            | 0,15-0,53                                | (23)   |
| Treatment failure in control group               | 0,22            | 0,19-0,29                                | (25)   |
| **Utility**                                      |                 |                                          |        |
| No hospitalization                               | 0,95            | 1,00-0,76                                | (31-34) |
| Hospitalization without acute complications       | 0,88            | 1,00-0,70                                | (35,36) |
| Hospitalization with acute complications         | 0,59            | 0,70-0,47                                | (35,36) |
| PICU without acute complications                 | 0,73            | 0,87-0,58                                | (35,36) |
| PICU with acute complications                    | 0,51            | 0,60-0,40                                | (35,36) |
| HFNC effectiveness                                |                 |                                          |        |
| Relative risk of reduction of treatment failure  | 0,57            | 0,45-0,72                                | (25)   |

### Interventions

Information regarding the effect of HFNC was extracted from a recent randomized clinical trial included after a systematic review, as discussed above, that compared HFNC with oxygen by nasal cannula (control group) in infants with bronchiolitis in the emergency setting (23). This clinical trial included infants with bronchiolitis in the emergency department or inpatient unit if they needed supplemental oxygen to keep oxygen saturation in the range of 92-98%, and excluded critically ill infants who had an immediate need for ICU admission or had cyanotic heart disease, a basal skull fracture, upper airway obstruction or a craniofacial malformation and infants who were receiving oxygen therapy at home.
Infants in this study were randomized and received humidified high flow oxygen at a rate of 2 liters per kilogram of body weight per minute. Infants in the standard group received supplemental oxygen through a nasal cannula up to a maximum of 2 liters per minute.

Cost analysis

All costs and information on resource use were collected directly from the medical invoices of 416 patients hospitalized with a bronchiolitis diagnosis (ICD-10 code: J21.0) in tertiary centers in Rionegro, Colombia, between January 2018 and December 2018. The reason for including 2018 costs is the fact that our country has undergone very little price variation in the last 10 years, especially in health services between different clinics and over time (24). Moreover, the proportions of each of the costs remain relatively constant, with few variations in their composition in the last ten years (24). The direct costs considered in the analysis include medical consultation at the emergency room, specialist referrals, chest physiotherapy, diagnosis support (laboratory, electrocardiogram, x-ray, etc.), medication (oxygen, nebulization, antibiotics, corticosteroids, bronchodilators, etc.), medical devices, hotel services at the intensive care unit, hotel services in a general medical ward. We have used US dollars (currency rate: US$ 1.00 = COP$ 3,000) (25) to express all costs in the study. To evaluate the indirect costs associated with the loss of parents’ productivity, the human capital method was used, assuming that everyone receives an income of at least legal minimum wage for formal or informal work. The cost-opportunity of the productivity loss at the workplace and the caregiver was assessed based on minimum wage without including transportation assistance for 2019 (US$ 229.81 per month). The legal minimum wage approved by the government was taken as a reference and not an average or median wage thereof, given that in Colombia over 75% of the population earns this amount (26). Because all patients with bronchiolitis included were children, we assumed that at least one family member accompanied the patient permanently during hospitalization, since pediatric hospitals in the country usually only allow one companion per patient in hospital. The cost associated with transportation and food (not including overnight stays), was assumed to correspond to 50% of minimum wage per day.

Utilities

The utility values used for the QALY calculations were taken from the literature from the aforementioned systematic review. The utility value for hospitalization was 0.95 (27-30), whereas the utility value for PICU, given hospitalization, was 0.88 (31, 32). The utility value for hospitalization with acute complications was 0.59; it was 0.5 for PICU with acute complications (33, 34). The number of QALYs was calculated as the utility value given to a particular health state multiplied by the length of time spent in that state. Given that these utilities were extracted from studies in non-Colombian populations, a range was used for a one-way and probabilistic sensitivity analysis of around 20% of the utility's value.

Sensitivity analyses
The robustness of the economic model was evaluated with one-way sensitivity analyses and probabilistic sensitivity analyses in accordance with the recommendation of consolidated health economics evaluation reporting standards (35). Tornado diagrams were used as a graphical method for displaying one-way sensitivity analyses. Probabilistic sensitivity analyses were carried out using the Monte Carlo technique with a simulation of a hypothetical cohort of 10,000 patients, in which each parameter varied randomly according to certain distributions (beta distribution in the case of probabilities and gamma distribution in the case of costs) to generate expected cost utilities with 95% confidence intervals (95% CI). A cost-effectiveness acceptability curve was used to evaluate the uncertainty surrounding the cost-effectiveness of HFNC. We estimated the population expected value of perfect information to inform the expected cost of uncertainty (expected opportunity loss surrounding the decision) (36). Microsoft Excel® was used in all analyses.
## Table 2
Cost used in base case and sensitivity analyses

| Model input                                      | Base case value | SA range for one-way sensitivity analyses | Distribution |
|--------------------------------------------------|-----------------|------------------------------------------|--------------|
| **Intervention cost**                            |                 |                                          |              |
| HFNC per patient day                             | 58.19           | 50.2-61.5                                | γ(SD:58.19)  |
| **Hospitalization cost**                         |                 |                                          |              |
| Daily cost in pediatric ward                     | 48.82           | 47.64-50.00                              | γ(SD:3.20)   |
| Hospital length of stay (days)                   | 5.8             | 4.00-6.01                                | γ(SD:2.03)   |
| **PICU related cost**                            |                 |                                          |              |
| Daily cost in PICU                               | 327.35          | 326.26-328.43                            | γ(SD:5.49)   |
| PICU length of stay (days)                       | 10              | 9.01-15.05                               | γ(SD:3.08)   |
| **Emergency visit prior hospitalization cost**   |                 |                                          |              |
| Daily cost of emergency ward                     | 12.83           | 12.19-13.46                              | γ(SD:3.20)   |
| **Direct medical cost per patient-day**          |                 |                                          |              |
| Specialist referrals                             | 10.67           | 10.31-11.01                              | γ(SD:1.72)   |
| Chest physiotherapy                              | 5.15            | 4.90-5.39                                | γ(SD:1.23)   |
| Chest radiography                                | 2.84            | 2.70-2.98                                | γ(SD:0.73)   |
| Others diagnostic imaging                        | 0.01            | 0.0-0.022                                | γ(SD:0.08)   |
| Complete blood cell counts                       | 1.12            | 1.05-1.17                                | γ(SD:0.28)   |
| RSV test                                         | 2.71            | 2.83-3.03                                | γ(SD:2.72)   |
| Other laboratory tests                           | 4.40            | 4.23-4.47                                | γ(SD:0.37)   |
| Oxygen                                           | 1.37            | 1.28-1.45                                | γ(SD:0.41)   |
| Nebulization                                     | 16.23           | 1.28-1.45                                | γ(SD:4.52)   |
| LEV                                              | 1.10            | 1.07-1.13                                | γ(SD:0.16)   |
| Antibiotics systemics                            | 1.21            | 1.11-1.30                                | γ(SD:0.49)   |
| Systemic o Inhaled Corticosteroids               | 0.08            | 0.0-0.90                                 | γ(SD:4.18)   |
| Bronchodilators                                  | 0.04            | 0.03-0.04                                | γ(SD:0.02)   |
| Other drugs                                      | 0.65            | 0.60-0.68                                | γ(SD:0.04)   |
| Medical devices                                  | 10.24           | 9.71-10.76                               | γ(SD:2.66)   |
Results

The calculated QALYs per patient were 0.9141 (95% CI 0.913-0.915) in the HFNC group and 0.9105 (95% CI 0.910-0.911) in the control group. The expected cost per patient was US$ 368 (95% CI US$ 323-411) for HFNC and US$ 441 (95% CI US$ 384-498) for the control group per patient. The strategy control was dominated by HFNC with a negative incremental cost-effectiveness ratio, Table 3. The cost-effectiveness plane is presented in Figure 2.

| Strategy | Cost (US$) | Difference | QUALYs | Difference | C/E | Marg C/E |
|----------|------------|------------|--------|------------|-----|----------|
| HFNC     | $ 368.89   | 0.91       |        |            | 403.55 |
| Control  | $ 441.37   | -72.46     | 0.91   | 0.004      | 484.75 (Dominated) |

Sensitivity analysis

Sensitivity analyses of parameters showed that the cost-effectiveness of HFNC was sensitive to the probability of hospitalization, Figure 3, without any threshold having been identified. For the entire range of this probability, a higher expected value was consistently detected in the HFNC strategy over the control group. Likewise, HFNC was always the cost-effectiveness strategy for all ranges of thresholds, Figure 3. The population EVPI for a threshold of US$ 20,000 was US$ 19,000, Figure 4.

Discussion

Our study suggests that nebulized HFNC is unequivocally cost-effective and dominant over the control strategy, achieving better outcomes at a lower cost in hospitalized patients with bronchiolitis. The potential magnitude of cost savings for the health system (US$ 72 per patient), especially in a middle-income country, is not negligible if we consider that in our country we have around 95,000 annual cases of children under 2 years old being hospitalized with acute respiratory infections (21). Our findings provide inputs for changes in clinical practice guidelines in similar settings, where efficiency in the allocation of health resources can be maximized.

Common concerns regarding the adoption of technologies relate to safety and effectiveness. Current evidence is conclusive regarding the safety of HFNC. In a recent systematic review of seven RTCs, no severe adverse events and no increased risk of air leak syndromes were reported (9). Only mild skin lesions were reported in under 3% of patients. In addition, parents and carers favored HFNC because of the ability to feed and overall comfort (9, 37). This aspect differs from CPAP, which is usually not well tolerated and interferes with patients’ normal care, and is associated with a higher risk of air leak.
syndromes (38). In terms of HFNC's effectiveness, the evidence is still debatable, with studies for and against its use concerning CN or CPAP in children with moderate or severe bronchiolitis both existing. The HFNC has been demonstrated to have had a beneficial effect on treatment failure, but many authors criticize this effect for the absence of effects on other related outcomes. For example, only one clinical trial included in the previously mentioned systematic review (39) found an effect on LOS and the duration of oxygen therapy,

and in none of the trials included was there an effect on the probability of PICU transfer. It is clear that there was no impact in this trial on the risk of admission to PICU because all patients with CN failure went onto HFNC, while those with HFNC failure went directly to PICU in these studies. This therefore underestimated the impact on this outcome and affected the difference in hospital stay rates and the duration of oxygen therapy. Indeed, over 60% of patients with a failure of standard oxygen therapy that switched to HFNC successfully recuperated (23, 37).

There is clearly a need for more clinical trials with standardized oxygen weaning protocols, but this therapy currently constitutes an optimal resource prior to mechanical ventilation. While our study showed only a slight effect on utilities between the two strategies evaluated, due to the fact that HFNC does not directly impact the chance of complications, HFNC has a significant positive impact on the cost because it reduces the use of secondary resources, especially those arising from PICU admission. These findings arose from a previous economic study carried out in parallel during a clinical trial, demonstrating that the HFNC arm required fewer resources than the CN arm (37). This is particularly important in scenarios with more limited economic resources. In at least four observational studies carried out in developing countries, a significantly lower proportion of children were transferred to PICU before the initial HFNC in emergency settings (5, 7, 40, 41). Indeed, clinical trials published until now with larger sample sizes show that the magnitude of the effect of HFNC was higher in hospitals without on-site PICUs than in hospitals with on-site PICUs. This escalation of care occurred at a rate of 7% in the HFNC group compared to 28% in the standard therapy group, while in hospitals with on-site PICUs this endpoint occurred at 14% in the HFNC group and 20% in the standard therapy group (23). Without a doubt, and reinforced by our results, the use of HFNC in emergency settings is an efficient alternative for infants with moderate-severe bronchiolitis to optimize the cost in scenarios without on-site PICUs or with limited economical resources.

A very important aspect of our model is that it was robust to changing the model's utility and cost values. HFNC was always the most cost-effective strategy in all ranges of thresholds evaluated with a low population EVPI. This was consistent with the finding that, although our utilities were collected from other populations, our results did not change when exploring the change in the ICER in the range of values of each utility explored. The same happens with costs. Although the resources, frequencies of use, and costs were collected from tertiary centers in Rionegro and not from a national study of all hospitals in Colombia, modifications to their values in the sensitivity analysis also did not significantly change the ICER. These aspects give us confidence in relation to the ability to make decisions based on our results. As is always necessary in science, more studies are needed to replicate our results (42). Our study has some limitations. The cost data were collected retrospectively. Bronchiolitis treatment and the costs in
question, including hospital prices, did not markedly change. Furthermore, our country has been characterized by having very low price variation in the last 10 years, especially in terms of health services (24). Additionally, we use utilities extracted from the literature and not estimated directly from our population. As was mentioned previously, the reliability and robustness of the results were evaluated using sensitivity analyses. However, an additional strength is the perspective of the society on which the economic analysis was focused, which allows a faster transfer of results to health policies.

In conclusion, HFNC in emergency settings was cost-effective for the hospital treatment of infants with moderate or severe bronchiolitis. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines and should be replicated to validate their results in other countries.

Declarations

Ethical approval and consent to participate:

This article does not contain any studies with human or animal participants performed by any of the authors.

Consent for publication:

All author consent this paper for publication

Availability of Data and Materials:

The raw data supporting your findings can be request to CIEMTO (https://http://ciemto.medicinaudea.co/)

Conflict of Interest:

The authors declare that they have no conflict of interest.

Funding:

There is no funding source.

Author Contribution:

JAB., RAC., CERM., contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript.
Acknowledgements:
none

References
1. Manley BJ, Owen L, Doyle LW, Davis PG. High-flow nasal cannulae and nasal continuous positive airway pressure use in non-tertiary special care nurseries in Australia and New Zealand. J Paediatr Child Health. 2012;48(1):16-21.
2. Zielinska A, Jassem-Bobowicz JM, Kwiatkowska J. Oxygen therapy with high-flow nasal cannulas in children with acute bronchiolitis. Anaesthesiol Intensive Ther. 2019;51(1):51-5.
3. Joseph MM, Edwards A. Acute bronchiolitis: assessment and management in the emergency department. Pediatr Emerg Med Pract. 2019;16(10):1-24.
4. Mikalsen IB, Davis P, Oymar K. High flow nasal cannula in children: a literature review. Scand J Trauma Resusc Emerg Med. 2016;24:93.
5. Hoffman E, Reichmuth KL, Cooke ML. A review of the use of high-flow nasal cannula oxygen therapy in hospitalised children at a regional hospital in the Cape Town Metro, South Africa. S Afr Med J. 2019;109(4):272-7.
6. Hoffman SB, Terrell N, Driscoll CH, Davis NL. Impact of High-Flow Nasal Cannula Use on Neonatal Respiratory Support Patterns and Length of Stay. Respir Care. 2016;61(10):1299-304.
7. Talamoni HL, Buendia JA, Pisapia ND, Sanchez aa, al. e. Non-Invasive Ventilation in Patients Hospitalized with Severe Bronchiolitis. American Journal of Respiratory and Critical Care Medicine. 2015;191:A4762.
8. Lodeserto FJ, Lettich TM, Rezaie SR. High-flow Nasal Cannula: Mechanisms of Action and Adult and Pediatric Indications. Cureus. 2018;10(11):e3639.
9. Moreel L, Proesmans M. High flow nasal cannula as respiratory support in treating infant bronchiolitis: a systematic review. Eur J Pediatr. 2020;179(5):711-8.
10. Wang J, Lee KP, Chong SL, Loi M, Lee JH. High flow nasal cannula in the emergency department: indications, safety and effectiveness. Expert Rev Med Devices. 2018;15(12):929-35.
11. Slain KN, Shein SL, Rotta AT. The use of high-flow nasal cannula in the pediatric emergency department. J Pediatr (Rio J). 2017;93 Suppl 1:36-45.
12. datos Ud. ¿Cuántas camas de UCI por persona hay en Colombia? El tiempo. 2020 28/03/2020.
13. Ferolla FM, Hijano DR, Acosta PL, Rodriguez A, Duenas K, Sancilio A, et al. Macronutrients during pregnancy and life-threatening respiratory syncytial virus infections in children. Am J Respir Crit Care Med. 2013;187(9):983-90.
14. Caballero MT, Polack FP. Respiratory syncytial virus is an "opportunistic" killer. Pediatr Pulmonol. 2018;53(5):664-7.
15. Arraut PB, Lesmes, A.C. Caracterización de la población con bronquiolitis en la Clínica Infantil Colsubsidio en el año 2013 Universidad del Rosario 2013 [Available from: http://repository.urosario.edu.co/bitstream/handle/10336/10515/53106146-2015.pdf?sequence=1.

16. Pineros JG, Baquero H, Bastidas J, García J, Ovalle O, Patino CM, et al. Respiratory syncytial virus infection as a cause of hospitalization in population under 1 year in Colombia. J Pediatr (Rio J). 2013;89(6):544-8.

17. Rodríguez-Martínez CE, Sossa-Briceno MP, Castro-Rodríguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol (Madr). 2020;48(1):56-61.

18. Ávila García IA, Valero Garzón A, Pira Paredes LÁ, Socha Rodríguez JP. Factores de riesgo identificados en niños que ingresaron a la unidad de cuidado intensivo pediátrico por bronquiolitis severa en el hospital occidente de Kennedy durante julio de 2007 a junio de 2009 Bogota: Universidad Militar Nueva Granada; 2009 [150]. Available from: https://repository.unimilitar.edu.co/handle/10654/10335.

19. Rodríguez-Martínez CE, Sossa-Briceno MP, Nino G. Predictors of prolonged length of hospital stay for infants with bronchiolitis. J Investig Med. 2018;66(6):986-91.

20. Rodríguez-Martínez CE, Sossa-Briceno MP, Castro-Rodríguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol (Madr). 2019.

21. Instituto, Nacional, Salud d. Infeccion respiratoria aguda en Colombia 2017 [05/07/2019]. Available from: https://www.ins.gov.co/buscador-eventos/Informe%20IRA%20Final%202017.pdf.

22. D Sinisterra, Buendía J. Cost Illness Of Rsv Infection In Colombia. Value in Health. 2017;20(9):A923–A4.

23. Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, et al. A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis. N Engl J Med. 2018;378(12):1121-31.

24. Estadisticas DAN. Índice de Precios al Consumidor - IPC 2020 [Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc.

25. la Bd, Republica. Tasa Representativa del Mercado (TRM - Peso por dólar) 2019 [cited 2020. Available from: https://www.banrep.gov.co/es/estadisticas/trm.

26. Departamento, Nacional, (DANE) DE. Archivo Nacional de Datos 2019 [Available from: https://sitios.dane.gov.co/anda-index/.

27. Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89(7):673-8.

28. Sanchez-Luna M, Burgos-Pol R, Oyaguez I, Figueras-Aloy J, Sanchez-Solis M, Martinon-Torres F, et al. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm
infants: update based on the clinical evidence in Spain. BMC Infect Dis. 2017;17(1):687.

29. Blanken MO, Frederix GW, Nibbelke EE, Koffijberg H, Sanders EAM, Rovers MM, et al. Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants. Eur J Pediatr. 2018;177(1):133-44.

30. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ. 2010;11(1):105-15.

31. Jones S, Rantell K, Stevens K, Colwell B, Ratcliffe JR, Holland P, et al. Outcome at 6 months after admission for pediatric intensive care: a report of a national study of pediatric intensive care units in the United kingdom. Pediatrics. 2006;118(5):2101-8.

32. Meijboom MJ, Rozenbaum MH, Benedictus A, Luytjes W, Kneyber MC, Wilschut JC, et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands. Vaccine. 2012;30(31):4691-700.

33. Shiri T, Khan K, Keaney K, Mukherjee G, McCarthy ND, Petrou S. Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of Interventions. Value Health. 2019;22(11):1329-44.

34. Chiou CF, Weaver MR, Bell MA, Lee TA, Krieger JW. Development of the multi-attribute Pediatric Asthma Health Outcome Measure (PAHOM). Int J Qual Health Care. 2005;17(1):23-30.

35. Husereau D, Drummond M, Petrou S, Carswell C, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049.

36. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making. 1998;18(1):95-109.

37. Kepreotes E, Whitehead B, Attia J, Oldmeadow C, Collison A, Searles A, et al. High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. Lancet. 2017;389(10072):930-9.

38. Vahlkvist S, Jurgensen L, la Cour A, Markoew S, Petersen TH, Kofoed PE. High flow nasal cannula and continuous positive airway pressure therapy in treatment of viral bronchiolitis: a randomized clinical trial. Eur J Pediatr. 2020;179(3):513-8.

39. Ergul AB, Caliskan E, Samsa H, Gokcek I, Kaya A, Zararsiz GE, et al. Using a high-flow nasal cannula provides superior results to OxyMask delivery in moderate to severe bronchiolitis: a randomized controlled study. Eur J Pediatr. 2018;177(8):1299-307.

40. Bassiouny MR, Gupta A, el Bualy M. Nasal continuous positive airway pressure in the treatment of respiratory distress syndrome: an experience from a developing country. J Trop Pediatr. 1994;40(6):341-4.

41. Monteverde E, Fernandez A, Ferrero F, Barbaro C, De Lillo L, Lavitola M, et al. High-flow nasal cannula oxygen therapy in infants with acute lower respiratory tract infection. An experience in hospitals of the City of Buenos Aires. Arch Argent Pediatr. 2019;117(5):286-93.

42. Buendia JA. [Attitudes, knowledge and beliefs of patient about anti-hypertensive drugs]. Biomedica. 2012;32(4):578-84.